Skip to main content
. 2016 Nov 4;7(48):78255–78268. doi: 10.18632/oncotarget.13126

Figure 2. RPL26 modulates TAp73 protein stability in part via MDM2.

Figure 2

A. The levels of RPL26, TAp73 and actin transcripts were measured in SW480 cells, which were transfected with an empty vector or a vector expressing RPL26 for 48 h. B.-C. The level of RPL26, TAp73 and actin transcripts was measured in SW480 cells B. or p53−/− HCT116 cells C., which were transfected with scrambled siRNA or siRNA against RPL26 for 72 h. D.-E. The half-life of TAp73 protein was determined in p53−/− HCT116 cells, which were transfected with an empty vector D. or a vector expressing RPL26 E. for 48 h along with treatment of cycloheximide for various times. F. The levels of MDM2, TAp73 and actin proteins were measured in p53−/− HCT116 and MDM2-knockout p53−/− HCT116 cells. G.-H. The half-life of TAp73 protein was determined in p53−/− HCT116 and MDM2-knockout p53−/− HCT116 cells treated with cycloheximide for various times. I. The levels of MDM2, RPL26, TAp73 and actin proteins were measured in p53−/− HCT116 and MDM2-knockout p53−/− HCT116 cells, which were transfected with scramble siRNA or RPL26 siRNA as indicated for 72 h.